Peregrine: Continuing to Accumulate on Any Dips

PPHM: Shares of Peregrine traded with some strength on Monday after the company opened trading after having have conducted a 1:5 reverse split.
The company also took the opportunity on Monday morning to announce that former Genentech Senior Executive Dr. Robert Garnick has joined Peregrine as the Head of Regulatory Affairs.

I maintain that PPHM is full of future potential based on the bavituximab and Cotara pipeline, although those products have yet to hit Phase III.

I'll continue to accumulate on any dips.

Of note, the stock will continue trading as PPHMD until the end of the month.

Disclosure: VFC is long PPHM.